Steven Grant
About
Steven Grant is a scholar working on Molecular Biology, Hematology and Oncology.
According to data from OpenAlex, Steven Grant has authored 451 papers receiving a total of 23.2k indexed citations (citations by other indexed papers that have themselves been cited), including 338 papers in Molecular Biology, 153 papers in Hematology and 112 papers in Oncology. Recurrent topics in Steven Grant's work include Histone Deacetylase Inhibitors Research (104 papers), Cell death mechanisms and regulation (102 papers) and Acute Myeloid Leukemia Research (90 papers). Steven Grant is often cited by papers focused on Histone Deacetylase Inhibitors Research (104 papers), Cell death mechanisms and regulation (102 papers) and Acute Myeloid Leukemia Research (90 papers). Steven Grant collaborates with scholars based in United States, Russia and Canada. Steven Grant's co-authors include Paul Dent, Yun Dai, Mohamed Rahmani, W. David Jarvis, Roberto R. Rosato, Paul B. Fisher, Jorge A. Almenara, Adly Yacoub, Xin‐Yan Pei and Richard Kolesnick and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Steven Grant
446 papers receiving 22.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Steven Grant United States | 79 | 16.7k | 6.3k | 3.6k | 2.3k | 2.2k | 451 | 23.2k | ||
| James A. McCubrey United States | 79 | 16.1k 1.0× | 6.8k 1.1× | 2.6k 0.7× | 3.9k 1.7× | 3.2k 1.5× | 421 | 24.9k | ||
| Kapil N. Bhalla United States | 87 | 17.3k 1.0× | 5.9k 0.9× | 6.5k 1.8× | 2.2k 1.0× | 2.8k 1.3× | 378 | 26.0k | ||
| Anthony Letai United States | 62 | 12.2k 0.7× | 4.5k 0.7× | 3.7k 1.0× | 2.1k 0.9× | 2.9k 1.3× | 175 | 18.2k | ||
| Paul Dent United States | 81 | 15.6k 0.9× | 7.0k 1.1× | 1.6k 0.4× | 2.4k 1.0× | 2.1k 1.0× | 388 | 23.1k | ||
| Andrew L. Kung United States | 81 | 16.6k 1.0× | 6.6k 1.1× | 4.1k 1.2× | 4.6k 2.0× | 2.9k 1.3× | 285 | 24.2k | ||
| David C.S. Huang Australia | 82 | 20.4k 1.2× | 6.2k 1.0× | 2.8k 0.8× | 2.5k 1.1× | 6.7k 3.1× | 236 | 28.2k | ||
| Brett P. Monia United States | 77 | 13.9k 0.8× | 3.3k 0.5× | 1.8k 0.5× | 3.4k 1.4× | 1.7k 0.8× | 274 | 21.8k | ||
| John L. Cleveland United States | 78 | 14.8k 0.9× | 6.8k 1.1× | 1.6k 0.4× | 3.3k 1.4× | 4.7k 2.2× | 224 | 22.7k | ||
| Nicholas Mitsiades United States | 66 | 10.1k 0.6× | 4.5k 0.7× | 4.6k 1.3× | 2.4k 1.0× | 1.9k 0.9× | 172 | 15.3k | ||
| Ricky W. Johnstone Australia | 77 | 18.7k 1.1× | 7.8k 1.2× | 2.0k 0.6× | 2.2k 0.9× | 5.3k 2.5× | 248 | 25.4k |
Countries citing papers authored by Steven Grant
Since
Specialization
Citations
This map shows the geographic impact of Steven Grant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Grant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Grant more than expected).
Fields of papers citing papers by Steven Grant
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Steven Grant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Grant. The network helps show where Steven Grant may publish in the future.
Co-authorship network of co-authors of Steven Grant
This figure shows the co-authorship network connecting the top 25 collaborators of Steven Grant. A scholar is included among the top collaborators of Steven Grant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Grant. Steven Grant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sharma, Kanika, et al.. (2023). Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax. Clinical Cancer Research. 29(7). 1332–1343.
2.
Dastur, Anahita, Carlotta Costa, August Williams, et al.. (2018). NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research. 25(1). 312–324.
3.
Rahmani, Mohamed, Xin‐Yan Pei, Rebecca E. Parker, et al.. (2018). Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Research. 78(11). 3075–3086.
4.
Rahmani, Mohamed, et al.. (2014). PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo. Clinical Cancer Research. 20(18). 4849–4860.
5.
Nguyen, Tri K. & Steven Grant. (2013). Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism. Molecular Cancer Therapeutics. 13(3). 662–674.
6.
Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883.
7.
Dai, Yun, Shuang Chen, Maciej Kmieciak, et al.. (2013). The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair. Molecular Cancer Therapeutics. 12(6). 878–889.
8.
Chen, Shuang, Yun Dai, Li Wang, et al.. (2012). CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies. Cancer Research. 72(16). 4225–4237.
9.
Rahmani, Mohamed, Mandy Mayo Aust, Elisa Attkisson, et al.. (2012). Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism. Cancer Research. 73(4). 1340–1351.
10.
Dasmahapatra, Girija, Hiral Patel, Tri Q. Nguyen, Elisa Attkisson, & Steven Grant. (2012). PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo. Clinical Cancer Research. 19(2). 404–414.
11.
Nguyen, Tri, Yun Dai, Elisa Attkisson, et al.. (2011). HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo. Clinical Cancer Research. 17(10). 3219–3232.
12.
Park, Margaret A., Adly Yacoub, Hossein A. Hamed, et al.. (2011). Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells. Cancer Research. 71(14). 4955–4967.
13.
Park, Margaret A., Clint Mitchell, Guo Zhang, et al.. (2010). Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+- De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway. Cancer Research. 70(15). 6313–6324.
14.
Park, Margaret A., Roland Reinehr, Dieter Häussinger, et al.. (2010). Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells. Molecular Cancer Therapeutics. 9(8). 2220–2231.
15.
Walker, Teneille, Clint Mitchell, Margaret A. Park, et al.. (2010). 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species. Molecular Cancer Therapeutics. 9(5). 1378–1395.
16.
Dash, Rupesh, Joanna E. Richards, Zhao-zhong Su, et al.. (2010). Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine. Cancer Research. 70(12). 5034–5045.
17.
Zhang, Guo, Margaret A. Park, Clint Mitchell, et al.. (2008). Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation. Clinical Cancer Research. 14(17). 5385–5399.
18.
Park, Margaret A., Guo Zhang, Clint Mitchell, et al.. (2008). Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Molecular Cancer Therapeutics. 7(9). 2633–2648.
19.
Dai, Yun, et al.. (2008). Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research. 14(2). 549–558.
20.
Rosato, Roberto R., et al.. (2007). The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation. Cancer Research. 67(19). 9490–9500.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by James A. McCubrey Breakdown of academic impact, for papers by Kapil N. Bhalla Breakdown of academic impact, for papers by Anthony Letai Breakdown of academic impact, for papers by Paul Dent Breakdown of academic impact, for papers by Andrew L. Kung Breakdown of academic impact, for papers by David C.S. Huang Breakdown of academic impact, for papers by Brett P. Monia Breakdown of academic impact, for papers by John L. Cleveland Breakdown of academic impact, for papers by Nicholas Mitsiades Breakdown of academic impact, for papers by Ricky W. Johnstone